Camagüey, January 4. – PORVAC vaccines against classical swine fever (CSF) and GAVAC against ticks from livestock produced by the Center for Genetic Engineering and Biotechnology (CIGB) in the province of Camaguey have strengthened their presence on the national market in 2018.
More than one million cattle across the country benefit from the use of HAVAC, an antigen designed in that institution for integrated tropical tick control Rhipicephalus (boophilus) microplus, the most common in Cuban falls, as confirmed by the Cuban news agency Nemesis González Fernández, v.d. director of CIGB.
By the end of 2018, more than two million 600 thousand doses of the vaccine had been commercialized throughout the national territory, a figure higher than the previous year, as part of a multi-sectoral strategy involving the Ministry of Agriculture, the Ministry of Agriculture and SGBB. Department of Animal Health and other persons.
In the case of ROVAK, whose large-scale production at the Camagüey Biotechnology Center started in the recently completed year, it already has presence in the genetic units and multipliers of the pig industry in all provinces, which are supplied in a pyramid scheme.
By 2019, it is expected to achieve the distribution of 1.2 million doses of this subunit vaccine, derived from the combination of virus and pig proteins, and more effective and safer than those of the attenuated virus that exist on the market, González Fernández said.
In 2018, more than 954,600 doses of PORVAC were sold, which also eradicated the vertical transmission of the mothers virus to posterity through the placenta, which gives PORVAC high added value, more if He says PPC is one of the diseases that cause more damage in the world pig industry.
In 2019, CIGB Camaguey intends to continue to strengthen the presence of its products in the national market and to attract investments to improve its installed technological capacity. (ACN) (Photo: Archives)